The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma
Abstract
RATIONALE: Accumulation of eosinophils in the bronchial mucosa of individuals with asthma is considered to be a central event in the pathogenesis of asthma. In animal models, airway eosinophil recruitment and airway hyperresponsiveness in response to allergen challenge are reduced by specific targeting of interleukin-5. A previous small dose-finding study found that mepolizumab, a humanized anti-interleukin-5 monoclonal antibody, had no effect on allergen challenge in humans. OBJECTIVES: To investigate the effect of three intravenous infusions of mepolizumab, 250 or 750 mg at monthly intervals, on clinical outcome measures in 362 patients with asthma experiencing persistent symptoms despite inhaled corticosteroid therapy (400-1,000 mug of beclomethasone or equivalent). METHODS: Multicenter, randomized, double-blind, placebo-controlled study. MEASUREMENTS AND MAIN RESULTS: Morning peak expiratory flow, forced expiratory volume in 1 second, daily beta(2)-agonist use, symptom scores, exacerbation rates, and quality of life measures. Sputum eosinophil levels were also measured in a subgroup of 37 individuals. Mepolizumab was associated with a significant reduction in blood and sputum eosinophils in both treatment groups (blood, P < 0.001 for both doses; sputum, P = 0.006 for 250 mg and P = 0.004 for 750 mg). There were no statistically significant changes in any of the clinical end points measured. There was a nonsignificant trend for decrease in exacerbation rates in the mepolizumab 750-mg treatment group (P = 0.065). CONCLUSIONS: Mepolizumab treatment does not appear to add significant clinical benefit in patients with asthma with persistent symptoms despite inhaled corticosteroid therapy. Further studies are needed to investigate the effect of mepolizumab on exacerbation rates, using protocols specifically tailored to patients with asthma with persistent airway eosinophilia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Predominant TH2-like Bronchoalveolar T-Lymphocyte Population in Atopic Asthma
Robinson, D. S., Hamid, Q., Ying, S., Tsicopoulos, A., Barkans, J., Bentley, A. M., Corrigan, C., Durham, S. R., & Kay, A. B. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260504 · Cited by 2,768
Self-citationEosinophilic Inflammation in Asthma
Bousquet, J., Chanez, P., Lacoste, J. Y., Barnéon, G., Ghavanian, N., Enander, I., Venge, P., Ahlstedt, S., Simony-Lafontaine, J., Godard, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010113231505 · Cited by 2,499
Leckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Self-citationAsthma exacerbations and sputum eosinophil counts: a randomised controlled trial
Green, R. H., Brightling, C. E., McKenna, S., Hargadon, B., Parker, D., Bradding, P., Wardlaw, A. J., & Pavord, I. D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11679-5 · Cited by 1,755
Foster, P. S., Hogan, S. P., Ramsay, A. J., Matthaei, K. I., & Young, I. G. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.195 · Cited by 1,370
WENZEL, S. E., SCHWARTZ, L. B., LANGMACK, E. L., HALLIDAY, J. L., TRUDEAU, J. B., GIBBS, R. L., & CHU, H. W. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.3.9812110 · Cited by 1,235
Self-citationGreen, R. H. (2002) · Thorax · doi:10.1136/thorax.57.10.875 · Cited by 848
Flood-Page, P., Menzies-Gow, A., Phipps, S., Ying, S., Wangoo, A., Ludwig, M. S., Barnes, N., Robinson, D., & Kay, A. B. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17974 · Cited by 841
Self-citationExpression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma.
Hamid, Q., Azzawi, M., Ying, S., Moqbel, R., Wardlaw, A. J., Corrigan, C. J., Bradley, B., Durham, S. R., Collins, J. V., & Jeffery, P. K. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115166 · Cited by 833
Flood-Page, P. T., Menzies-Gow, A. N., Kay, A. B., & Robinson, D. S. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-789oc · Cited by 808
Self-citationValidation of a Standardized Version of the Asthma Quality of Life Questionnaire
Juniper, E. F., Buist, A. S., Cox, F. M., Ferrie, P. J., & King, D. R. (1999) · Chest · doi:10.1378/chest.115.5.1265 · Cited by 714
Yamaguchi, Y., Hayashi, Y., Sugama, Y., Miura, Y., Kasahara, T., Kitamura, S., Torisu, M., Mita, S., Tominaga, A., & Takatsu, K. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.5.1737 · Cited by 608
Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations
Jayaram, L., Pizzichini, M. M., Cook, R. J., Boulet, L.-P., Lemière, C., Pizzichini, E., Cartier, A., Hussack, P., Goldsmith, C. H., Laviolette, M., et al. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00137704 · Cited by 603
Robinson, D., Hamid, Q., Bentley, A., Ying, S., Kay, A. B., & Durham, S. R. (1993) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(93)90175-f · Cited by 576
Self-citationYamaguchi, Y., Suda, T., Suda, J., Eguchi, M., Miura, Y., Harada, N., Tominaga, A., & Takatsu, K. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.1.43 · Cited by 514
Kips, J. C., O'Connor, B. J., Langley, S. J., Woodcock, A., Kerstjens, H. A. M., Postma, D. S., Danzig, M., Cuss, F., & Pauwels, R. A. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-525oc · Cited by 494
Anti–interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes
Garrett, J. K., Jameson, S. C., Thomson, B., Collins, M. H., Wagoner, L. E., Freese, D. K., Beck, L. A., Boyce, J. A., Filipovich, A. H., Villanueva, J. M., et al. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.10.049 · Cited by 362
Effects of an antibody to interleukin-5 in a monkey model of asthma.
Mauser, P. J., Pitman, A. M., Fernandez, X., Foran, S. K., Adams, G. K., Kreutner, W., Egan, R. W., & Chapman, R. W. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.2.7633694 · Cited by 319
Jatakanon, A., Kharitonov, S., Lim, S., & Barnes, P. J. (1999) · Thorax · doi:10.1136/thx.54.2.108 · Cited by 262
Use of an Anti–Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic Dermatitis
Plötz, S.-G., Simon, H.-U., Darsow, U., Simon, D., Vassina, E., Yousefi, S., Hein, R., Smith, T., Behrendt, H., & Ring, J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031261 · Cited by 259
Fahy, J. V., Wong, H., Liu, J., & Boushey, H. A. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.1.7599862 · Cited by 247
Hart, T. K., Cook, R. M., Zia-Amirhosseini, P., Minthorn, E., Sellers, T. S., Maleeff, B. E., Eustis, S., Schwartz, L. W., Tsui, P., Appelbaum, E. R., et al. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.116576 · Cited by 238
Elemental signals regulating eosinophil accumulation in the lung
Foster, P. S., Mould, A. W., Yang, M., Mackenzie, J., Mattes, J., Hogan, S. P., Mahalingam, S., Mckenzie, A. N. J., Rothenberg, M. E., Young, I. G., et al. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.790117.x · Cited by 226
Relationship between IL-4 and IL-5 mRNA Expression and Disease Severity in Atopic Asthma
HUMBERT, M., CORRIGAN, C. J., KIMMITT, P., TILL, S. J., BARRY KAY, A., & DURHAM, S. R. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.156.3.9610033 · Cited by 209
Nishinakamura, R., Miyajima, A., Mee, P., Tybulewicz, V., & Murray, R. (1996) · Blood · doi:10.1182/blood.v88.7.2458.bloodjournal8872458 · Cited by 208
Role of Interleukin-5 and Eosinophils in Allergen-Induced Airway Remodeling in Mice
Tanaka, H., Komai, M., Nagao, K., Ishizaki, M., Kajiwara, D., Takatsu, K., Delespesse, G., & Nagai, H. (2004) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2003-0305oc · Cited by 179
Gregory, B., Kirchem, A., Phipps, S., Gevaert, P., Pridgeon, C., Rankin, S. M., & Robinson, D. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.11.5359 · Cited by 143
Self-citationEffects of Terbutaline and Budesonide on Sputum Cells and Bronchial Hyperresponsiveness In Asthma
Aldridge, R. E., Hancox, R. J., Taylor, D. R., Cowan, J. O., WINN, M. C., Frampton, C. M., & Town, G. I. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.5.9906052 · Cited by 140
New insights into the relationship between airway inflammation and asthma
Wardlaw, A. J., Brightling, C. E., Green, R., Woltmann, G., Bradding, P. H., & Pavord, I. D. (2002) · Clinical Science · doi:10.1042/cs1030201 · Cited by 135
Liu, L. Y., Sedgwick, J. B., Bates, M. E., Vrtis, R. F., Gern, J. E., Kita, H., Jarjour, N. N., Busse, W. W., & KELLY, E. A. B. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.11.6459 · Cited by 126
Self-citationPhipps, S., Flood-Page, P. T., Menzies-Gow, A. N., Ong, Y. E., & Kay, A. B. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22619.x · Cited by 102
Self-citationCationic Proteins Induce Airway Hyperresponsiveness Dependent on Charge Interactions
Coyle, A. J., Ackerman, S. J., & Irvin, C. G. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/147.4.896 · Cited by 96
Shardonofsky, F. R., Venzor, J., Barrios, R. J., et al. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70138-7 · Cited by 55
Technology evaluation: mepolizumab, GlaxoSmithKline.
Gnanakumaran, G., & Babu, K. S. (2003) · PubMed · Cited by 28
Cited by
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
“While the anti-IL5 antibody, mepolizumab, was not beneficial in unselected adult patients with moderate asthma [321], when studied in severe asthma patients with persistent sputum”
BackgroundSelf-citationAsthma phenotypes: the evolution from clinical to molecular approaches
Wenzel, S. E. (2012) · Nature Medicine · doi:10.1038/nm.2678 · Cited by 2,412
Self-citationMepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,871
Metadata
- Authors
- Flood-Page, P., Swenson, C., Faiferman, I., Matthews, J., Williams, M., Brannick, L., Robinson, D., Wenzel, S., Busse, W., Hansel, T. T., Barnes, N. C., & on behalf of the International Mepolizumab Study Group
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-12-01
- Volume
- 176
- Issue
- 11
- Pages
- 1062-1071
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W1994585625
- Cited by
- 750
- References
- 35
- FWCI
- 23.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.